Corporate strategies and tactics for more effective drug development.
February 25, 2009
By:
George Koroneos, Online Content & News Editor
A sign of the times or a rash decision? In an effort to curb unnecessary costs, Pfizer kills development of two late-stage products rather than sink more money into them.
|
January 7, 2009
By:
George Koroneos, Online Content & News Editor
Merck isn't bragging about the positive data it received regarding the use of its landmark HPV vaccine in men. But the pharma giant also isn't wasting time submitting the info to FDA. Pharm Exec talked to the lead investigator behind the trials to find out why this could be another milestone for Merck.
|
September 17, 2008
By:
George Koroneos, Online Content & News Editor
Glaxo's cancer departments will be consolidated into one big division encompassing discovery, research, and trials. The move is expected to cost some jobs, but GSK hopes it will strengthen synergy within its R&D unit.
|
June 11, 2008
By:
George Koroneos, Online Content & News Editor
Swiss pharma giant Roche was abuzz at ADA, announcing that its new diabetes treatment is set for Phase III trials and commenting on future plans for failed CETP inhibitor dalcetrapib.
|
April 2, 2008
By:
George Koroneos, Online Content & News Editor
While some drugmakers are being pummeled for data on their "bad" cholesterol?lowering drugs, promising Phase II stats about its "good" cholesterol?raising CETP inhibitor has Roche smiling. Can it escape the torcetrapib curse?
|
January 9, 2008
By:
George Koroneos, Online Content & News Editor
Eli Lilly will help develop and market BioMS?s secondary progressive multiple sclerosis drug MBP8298, now in Phase III trials. If approved, the drug will be one of the only medications on the market to treat late-stage MS, a boon for both Lilly and BioMS.
|
December 12, 2007
By:
George Koroneos, Online Content & News Editor
Bristol-Myers Squibb halves its manufacturing division and looks to unmet needs for innovation. Expect new oncology, diabetes, and cardiovascular drugs as well as a more streamlined approach to manufacturing.
|
November 29, 2007
By:
George Koroneos, Online Content & News Editor
In an attempt to bring clinical trials into the 21st century, FDA and Duke launched a public–private partnership that will look at the current state of trials and determine what tools can be implemented to make trials safer and more efficient.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
